INCY - Incyte Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
78.42
-0.25 (-0.32%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close78.67
Open79.24
Bid77.65 x 1100
Ask79.99 x 1800
Day's Range77.94 - 79.47
52 Week Range57.00 - 96.44
Volume2,033,471
Avg. Volume1,728,846
Market Cap16.688B
Beta (3Y Monthly)1.23
PE Ratio (TTM)N/A
EPS (TTM)-0.51
Earnings DateFeb 13, 2019 - Feb 18, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est84.69
Trade prices are not sourced from all markets
  • Markit2 days ago

    See what the IHS Markit Score report has to say about Incyte Corp.

    # Incyte Corp ### NASDAQ/NGS:INCY View full report here! ## Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for INCY with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting INCY. ## Money flow ETF/Index ownership | Negative ETF activity is negative and may be weakening. The net inflows of $6.08 billion over the last one-month into ETFs that hold INCY are among the lowest of the last year and appear to be slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • ACCESSWIRE5 days ago

    Today's Research Reports on Trending Tickers: Incyte and CorMedix

    NEW YORK, NY / ACCESSWIRE / January 16, 2019 /U.S. markets rose on Tuesday as Netflix helped push the tech sector higher after announcing it would raise the price of its monthly membership. Tech giants ...

  • Here’s your guide to the upcoming biotechnology takeover wave
    MarketWatch5 days ago

    Here’s your guide to the upcoming biotechnology takeover wave

    Biotechnology companies have been hit so hard, Big Pharma is now picking them off one by one in takeovers. This makes biotech companies look very attractive. In the weakness, for example, Celgene (CELG) hit its lowest price-to-earnings ratio in history, or around six.

  • Why Yet Another Biotech Stock Is Grabbing Renewed Takeover Chatter
    Investor's Business Daily5 days ago

    Why Yet Another Biotech Stock Is Grabbing Renewed Takeover Chatter

    Incyte stock launched Tuesday after an analyst suggested its portfolio of cancer treatments could net the biotech stock an acquisition offer. Biotech deals have been rampant this month.

  • FANG Stocks, Cyclicals Lead Nasdaq, Dow Jones Up; This Sector Is Poised To Rally More
    Investor's Business Daily6 days ago

    FANG Stocks, Cyclicals Lead Nasdaq, Dow Jones Up; This Sector Is Poised To Rally More

    FANG and cloud computing stocks continued to advance bullishly and the Nasdaq showed strength. The Dow Jones industrial average and small caps lagged.

  • What's in Store for Merck in 2019 After a Solid Run in '18?
    Zacks7 days ago

    What's in Store for Merck in 2019 After a Solid Run in '18?

    Merck (MRK) looks well poised for 2019, carrying forward the momentum achieved last year.

  • 3 Biotech Stocks Bubbling Away
    Investopedia10 days ago

    3 Biotech Stocks Bubbling Away

    Merger and acquisition activity in the healthcare sector has biotech stocks soaring. Explore three stocks feeling the tailwind.

  • Markit12 days ago

    See what the IHS Markit Score report has to say about Incyte Corp.

    # Incyte Corp ### NASDAQ/NGS:INCY View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for INCY with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting INCY. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, ETFs holding INCY are favorable, with net inflows of $16.07 billion. Additionally, the rate of inflows is increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • 4 Biotechs That Are Potential Buyouts Post Celgene Deal
    Zacks13 days ago

    4 Biotechs That Are Potential Buyouts Post Celgene Deal

    We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2019.

  • Markit13 days ago

    See what the IHS Markit Score report has to say about Incyte Corp.

    # Incyte Corp ### NASDAQ/NGS:INCY View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding ## Bearish sentiment Short interest | Positive Short interest is extremely low for INCY with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting INCY. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, ETFs holding INCY are favorable, with net inflows of $16.07 billion. Additionally, the rate of inflows is increasing. ## Economic sentiment PMI by IHS Markit | Positive According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Why Agenus Stock Is Spiking Today
    Motley Fool14 days ago

    Why Agenus Stock Is Spiking Today

    Eli Lilly's acquisition of Loxo Oncology lit a fire underneath the cancer immunotherapy company today..

  • GlobeNewswire14 days ago

    Merus Announces IND Clearance for MCLA-145

    “We are pleased to announce the IND authorization to proceed from the FDA and to disclose more details around our latest Biclonics® program today,” said Andres Sirulnik, M.D., Ph. D., Executive Vice President and Chief Medical Officer of Merus. “Our preclinical work has demonstrated that MCLA-145 has the potential to overcome the known side effects of CD137 agonists currently in development and to address a significant unmet need in patient populations not benefitting from current immunotherapeutic agents. Discovered through an unbiased functional screening of multiple immunomodulatory target combinations, MCLA-145 is a Biclonics® T-cell agonist that binds with high affinity and specificity to human PD-L1 and CD137 in preclinical models.

  • Markit16 days ago

    See what the IHS Markit Score report has to say about Incyte Corp.

    This could indicate that investors who seek to profit from falling equity prices are not currently targeting INCY. According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.

  • 3 Big Stock Charts for Friday: Incyte, Schlumberger and Abbott Laboratories
    InvestorPlace17 days ago

    3 Big Stock Charts for Friday: Incyte, Schlumberger and Abbott Laboratories

    Led lower by Apple (NASDAQ:AAPL), which fell 10% on Thursday after issuing a rare revenue warning for its recently-completed quarter, the S&P 500 logged a 2.48% loss yesterday. Apple had help, to be clear. Advanced Micro Devices (NASDAQ:AMD) tumbled to the tune of 9.5%, and rival/peer Nvidia (NASDAQ:NVDA) wasn’t far behind with a 6% setback mostly in response to an impending class action lawsuit being prepared to levy against the latter company.

  • Merck Buys NASH Candidate, Keytruda Wins 5 Approvals in Japan
    Zacks17 days ago

    Merck Buys NASH Candidate, Keytruda Wins 5 Approvals in Japan

    Merck (MRK) exercises option to in-license an insulin sensitizer from NGM Biopharmaceuticals for NASH and type II diabetes. Its key drug Keytruda snaps up five new label expansion nods in Japan.

  • Reuters17 days ago

    Factbox - Bristol-Myers' $74 billion Celgene buy has investors looking for next deal

    By Liana B. Baker (Reuters) - Bristol-Myers Squibb Co's (BMY.N) announcement that it would buy Celgene Corp (CELG.O) for $74 billion has raised investors' hopes that a wave of consolidation among drugmakers ...

  • Why Celgene, Agenus, and Incyte Jumped Today
    Motley Fool17 days ago

    Why Celgene, Agenus, and Incyte Jumped Today

    Biotech was a popular sector today. Find out why.

  • TheStreet.com17 days ago

    Incyte Climbs on Guggenheim Upgrade

    climbed 7.60% to $68.39 Thursday after Guggenheim Partners upgraded the biopharmaceutical company from neutral to buy. A year ago, Wilmington, Delaware-based Incyte was trading at $100.98 a share. Separately, Incyte said that Christiana Stamoulis had been appointed executive vice president and CFO, effective Feb. 11, succeeding David Gryska, who retired at the end of 2018.

  • Business Wire18 days ago

    Incyte Appoints Christiana Stamoulis as Chief Financial Officer

    Incyte (INCY) today announced the appointment of Christiana Stamoulis as Executive Vice President and Chief Financial Officer, effective February 11, 2019. Ms. Stamoulis will succeed David Gryska who, as planned, retired from Incyte at the end of 2018. "We are very pleased to welcome Christiana to Incyte,” said Hervé Hoppenot, Chief Executive Officer of Incyte.

  • Do Analysts See Any Upside in BeiGene Stock?
    Market Realist23 days ago

    Do Analysts See Any Upside in BeiGene Stock?

    Of the 11 analysts covering BeiGene (BGNE), four have given it “strong buys,” and seven have given it “buys.” 

  • Understanding BeiGene’s Operational Performance
    Market Realist23 days ago

    Understanding BeiGene’s Operational Performance

    In its most recent quarter, BeiGene’s (BGNE) selling, general, and administrative expenses rose YoY (year-over-year) to $48.82 million from $15.64 million primarily due to an increased head count.

  • Assessing BeiGene Limited’s Gross Margin Trend
    Market Realist23 days ago

    Assessing BeiGene Limited’s Gross Margin Trend

    In the third quarter, BeiGene’s (BGNE) total revenue fell YoY (year-over-year) to $54.2 million from $220.21 million. During the quarter, it generated $10.24 million from the US market and $43.96 million from outside the United States. During the comparable period in 2017, it generated $137.4 million from the US market and $82.81 million from outside the United States.

  • Taking Stock of BeiGene’s Latest Performance
    Market Realist23 days ago

    Taking Stock of BeiGene’s Latest Performance

    BeiGene Limited (BGNE) is a biopharmaceutical company with a focus on bringing to market molecularly targeted and immuno-oncology drugs for the treatment of cancer. In this series, we’ll explore BeiGene’s financials, valuation, and analyst views.

  • See what the IHS Markit Score report has to say about Incyte Corp.
    Markit27 days ago

    See what the IHS Markit Score report has to say about Incyte Corp.

    This could indicate that investors who seek to profit from falling equity prices are not currently targeting INCY. Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.

  • Merck's sBLA for Keytruda in Lung Cancer Gets Extended Review
    Zackslast month

    Merck's sBLA for Keytruda in Lung Cancer Gets Extended Review

    FDA extends review period for label expansion application for Merck's (MRK) Keytruda in first-line lung cancer by three months. A decision is now expected in April 2019.